A phase II study of the dual mTOR inhibitor MLN0128 in patients with metastatic castration resistant prostate cancer von Graham, Laura, Banda, Kalyan, Torres, Alba, Carver, Brett S., Chen, Yu, Pisano, Katie, Shelkey, Greg, Curley, Tracy, Scher, Howard I., Lotan, Tamara L., Hsieh, Andrew C., Rathkopf, Dana E.

Volltext